DIACEUTICS PLC (AIM: DXRX) — Investment Research Note

Executive summary

Diaceutics is a UK-headquartered pharma-tech company whose DXRX platform provides diagnostic commercialisation services (real-world lab data, patient identification signals, physician engagement) to global pharma and biotech launching precision medicines. Across the past five years revenue has compounded from ~£13.9m (2020) to £38.4m (FY25) with an inflection year in 2025 that saw the business return to profitability (Adj EBITDA up 80% to £7.6m, 20% margin) and grow ARR by 19% to £20.0m. The most important valuation point is the operating-leverage inflection: gross margin is 82%, revenue is increasingly recurring, and adjusted EBITDA is now expanding 4x faster than revenue — but Q1 2026 growth decelerated to 15% (CC) and cash fell 42% during 2025 as pharma customers stretched receivables.

Fair value estimate

• Fair value range: 165p – 215p per share → implied market cap £140m – £182m
• Methodology: primary — forward EV/Sales and EV/EBITDA blend on FY26E (management guides 25% revenue growth, implying ~£48m; assuming Adj EBITDA margin ~24% gives ~£11.5m). At 2.5–3.5x forward sales and 12–15x forward Adj EBITDA (typical vertical SaaS with 20%+ growth and expanding margins), EV range is £120m–£172m. Add £7m net cash → equity value £127–£179m, or ~150–210p. Cross-check on EV/ARR (£20m FY25 ARR × 6–8x forward multiple assuming ARR grows to £24m) → £144–192m EV → similar range.
• Current market cap: £121.9m at 142p
• Absolute upside to mid (190p): ~34%; downside to low (165p): +16%

Sector context

Confirmed as Health Care / Health Care per ICB, though the business is more accurately categorised as healthcare information services / vertical SaaS. Growth and gross-margin profile (82%) sit above sector average; net-cash balance sheet is stronger than typical AIM healthcare peer; scale (£38m revenue) is well below listed peers. Closest listed comparators: Tempus AI (Nasdaq, referenced in the CEO's own commentary as a workflow-integration parallel), Craneware, Veeva Systems (much larger), and privately IQVIA's real-world data business.

Investment thesis

1. Platform inflection is now visible in the P&L. Adj EBITDA grew 80% on 20% revenue growth in FY25, margin expanded from 13% → 20%, and 105% NRR + 19% ARR growth mean the recurring base is scaling faster than reported revenue. Order book grew 56% to £38.9m with £21.1m locked in for 2026 2026-05-26 Final Results.
2. Deep, hard-to-replicate proprietary dataset with AI leverage. DXRX integrates lab, claims and physician data across 900+ labs and 970,000 patients influenced in 2025; management is explicitly deploying agentic AI across data ingestion, cohort building and physician-workflow integration — this is the kind of proprietary healthcare-data asset whose value increases as AI tooling matures 2026-05-26 Final Results; 2026-01-15 Trading Update.
3. Balance sheet supports the plan. Net cash of £7.3m, no debt, undrawn £2m overdraft, and 18 of top 20 global pharma as customers with average revenue per customer up 17% to £0.73m — customer concentration risk is real but revenue quality is genuine 2026-05-26 Final Results.

Key risks

1. Growth is decelerating and cash conversion has weakened. FY25 constant-currency growth of 24% is down from 39% in FY24; Q1 2026 further slowed to 15% CC. Cash dropped from £12.7m to £7.3m as pharma customers extended payment terms — cash flat at end-Q1 2026 despite collections 2026-05-26 Final Results.
2. Guidance discipline is imperfect. FY25 revenue of £38.4m came in below the £39.0m–£40.2m consensus range management themselves referenced; the "in line" characterisation obscures a modest miss 2026-05-26 Final Results.
3. Customer concentration and pharma cyclicality. One customer = 18% of FY25 revenue (up from 15% in 2024). 93% US customer exposure creates FX drag and puts revenue at the mercy of a small number of pharma renewal decisions in a year when many top pharma customers restructured brand budgets 2026-05-26 Final Results.

Operating leverage

Diaceutics is a genuine high-operating-leverage business at current scale. Gross margin is 82% (down from 88% due to £2m of expensed data costs in new therapeutic areas — a discretionary growth investment, not a structural erosion). The cost base is dominated by payroll (£21m of £38.6m in cost of sales + admin) which is largely fixed at the platform-and-team level; annual data spend of £6m and platform development spend of £3.7m are also broadly fixed. A 10–20% revenue beat over the FY26 guide would flow through at incremental margins well above 50% — Adj EBITDA could plausibly move from £11–12m (guided trajectory) to £15–17m on a 10–20% top-line surprise, roughly a 30–50% Adj EBITDA uplift for a 10–20% revenue surprise. The clear inflection observed between FY24 and FY25 (revenue +20%, Adj EBITDA +80%) is the empirical demonstration. The main constraint on the "long-tail" upside is that revenue is US-dollar-denominated and FX movement can materially compress or amplify the effect 2026-05-26 Final Results.

Value-trap signals

• Cash burn during a supposed "return to profitability" year — receivables ballooned from £14.8m to £19.7m, and cash fell despite reported PBT of £0.3m.
• Very small free float on AIM; concentrated Keeling family holdings (CEO Ryan Keeling, founder Peter Keeling still on board) — governance risk noted but not acute.
• Heavy intangible capitalisation (£6.4m capex in FY25 for datasets/platform vs £5.4m amortisation) — earnings quality is optically flattered by capitalisation; on a cash basis the business is close to breakeven, not truly profitable.
• Q1 2026 deceleration to 15% CC growth vs guided 25% for FY26 requires a strong H2 to hit the number.

Earnings vs. expectations

The disclosed record is mixed. FY24: Revenue of £32.2m against consensus of £30m (beat); Adj EBITDA marginally ahead. FY25 January trading update: guided revenue "in line with consensus" of £39.5m CC and Adj EBITDA "above consensus" of £7.1m — actual FY25 reported revenue was £38.4m (reported) / £40.0m (CC), so CC revenue was in line, reported was a modest miss; Adj EBITDA of £7.6m did beat the £7.1m consensus. Q1 2026 performance is characterised as "in line" but at 15% CC growth is meaningfully below the 25% full-year guide, implying a required H2 acceleration. Overall: mostly in-line to slight beats on EBITDA, in-line to slight misses on revenue, with a visible slowdown into 2026.

Conviction

Conviction: 3 (moderate). Anchors: (i) two years of clean audited financials with EY as auditor and detailed KPI disclosure (ARR, NRR, order book), (ii) methodology is well-suited (SaaS-like recurring-revenue model with peer comparables); (iii) balance sheet is transparent. Limits: (i) small AIM stock with only 2 years of Adj EBITDA at scale — the operating-leverage trajectory is inferred from a limited number of data points; (ii) Q1 2026 deceleration and cash-conversion weakness introduce meaningful uncertainty about the FY26 exit run-rate that drives the valuation.

Driver scoring

• ai_beneficiary: 58 — proprietary healthcare data asset genuinely benefits from agentic-AI adoption; explicit AI deployment across the platform; "AI-driven pharma platform" fits the target categories. But this is a small vertical SaaS, not a pick-and-shovels AI beneficiary, and much of the AI narrative is about internal efficiency rather than a new revenue line.
• operating_leverage: 78 — 82% gross margins, high fixed R&D and platform cost, expanding recurring revenue, empirically demonstrated inflection (Adj EBITDA +80% on revenue +20%).
• earnings_surprise_trend: 50 — mixed: revenue misses / EBITDA beats; Q1 2026 slowdown a caution flag.
• cyclicality: 35 — pharma R&D and commercial budgets are somewhat cyclical but healthcare is broadly defensive; not deeply cyclical.
• moat: 55 — proprietary lab-network data, embedded workflow (Epic integration in progress), 18 of top 20 pharma customers, PMx multi-year lock-in — narrow but real moat.
• leverage: 10 — net cash £7.3m, no debt, fortress-ish balance sheet.
• earnings_quality: 50 — heavy R&D capitalisation flatters reported earnings; cash conversion weakened in 2025; Adj EBITDA is £7.6m but operating cash flow after tax was only £1.2m.
• management_quality: 60 — founder-led, disciplined capital allocation, has delivered on the platform transition; not standout capital allocators (no buybacks despite low share price) but no red flags.
• growth_momentum: 60 — 20% reported / 24% CC growth in FY25, guided 25% FY26, but Q1 2026 at 15% shows decelerating momentum.

Overall score

580 / 1000. Fits the strategy partially: real operating leverage, fair-not-cheap valuation, credible AI-adjacent data asset, strong balance sheet — but AI-receiver angle is more "indirect vertical SaaS with proprietary data" than pure picks-and-shovels, and the Q1 2026 deceleration argues for waiting rather than chasing. Not a top-band buy at current price; a partial-fit "know it, would buy on weakness" name.